International Journal of Clinical Oncology最新文献

{"title":"Periodic tryptophan protein 1 promotes colorectal cancer growth via ribosome biogenesis.","authors":"Yuan Tian, Hao Zhang, Zeyu Xiang, Chunjie Xu, Hanbing Xue, Qing Xu","doi":"10.1007/s10147-025-02733-1","DOIUrl":"https://doi.org/10.1007/s10147-025-02733-1","url":null,"abstract":"<p><strong>Background: </strong>Periodic tryptophan protein 1 (PWP1) is a member of the WD-40 family, located at the nucleus. The study of PWP1 in malignant tumors is at the initial stage. Its role and mechanism in colorectal cancer (CRC) remain unclear.</p><p><strong>Methods: </strong>KEGG pathway analysis were used for bioinformatics analysis. The protein expression of PWP1 in the tissue microarrays was detected by immunohistochemical methods. Colony and CCK-8 were used for PWP1 function in vitro, and the orthotopic model was used to assess PWP1 function in vivo. The growth of CRC was tracked by the Living Imaging System. Immunofluorescence was used for the quantification of nascent rRNAs. Polysome fractionation analysis was used to detect mRNA abundance.</p><p><strong>Results: </strong>GEO database was used to identify differential genes with elevated expression in CRC and followed by a KEGG analysis, which revealed that the ribosome synthesis pathway was enriched in CRC, with PWP1 displaying the most significant differential expression. Subsequently, the results of both in vitro and in vivo experiments demonstrated that PWP1 knockdown inhibited the proliferation of CRC. The results of immunofluorescence demonstrated that PWP1 knockdown suppressed de novo rRNA synthesis. Then, the differential proteins were examined, and this revealed that the most significantly downregulated proteins were those associated with DNA replication and mismatch repair functions following PWP1 interference. Moreover, ribosome profiling demonstrated significant downregulation of mRNAs associated with above functions.</p><p><strong>Conclusion: </strong>We found that the PWP1-ribosome synthesis pathway is instrumental in achieving precise regulation of downstream signaling pathways, which in turn promote CRC growth.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study.","authors":"Yuriko Ishida, Satoshi Ikeda, Toshiyuki Harada, Jun Sakakibara-Konishi, Keiki Yokoo, Hajime Kikuchi, Tae Iwasawa, Toshihiro Misumi, Satoshi Konno, Takashi Ogura","doi":"10.1007/s10147-025-02732-2","DOIUrl":"10.1007/s10147-025-02732-2","url":null,"abstract":"<p><strong>Background: </strong>Interstitial pneumonia (IP) is a common comorbidity with poor prognosis in patients with non-small cell lung cancer (NSCLC) and a risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. This study aimed to assess the incidence, severity, and risk factors of ICI-induced pneumonitis in patients with NSCLC and idiopathic IP.</p><p><strong>Methods: </strong>This multicenter, retrospective study involved patients with advanced or recurrent NSCLC and comorbid idiopathic IP and receiving ICI monotherapy as the second or subsequent line. A board-certified radiologist centrally reviewed all computed tomography images at baseline and at the onset of pneumonitis. Logistic regression analysis with clinical, laboratory, and radiological variables was used to examine the risk factors for pneumonitis.</p><p><strong>Results: </strong>This study included 65 patients with a median age of 71 years, 98.5% of whom had a smoking history. Three ICIs were used and a median of three cycles. Honeycomb lung was present in 23.1% of the patients, and the median % forced vital capacity (FVC) was 95.0%. Notably, 23.1% of the patients exhibited all-grade pneumonitis and 15.4% exhibited grade ≥ 3 pneumonitis. No significant risk factors for pneumonitis were identified after univariate logistic regression analysis. The incidence and severity of ICI-induced pneumonitis did not differ between patients with and without honeycomb lung or with FVC ≥ 80% versus < 80%, respectively.</p><p><strong>Conclusion: </strong>In this retrospective analysis of patients with NSCLC, the risk of ICI-induced pneumonitis did not differ based on radiologic patterns of comorbid IP, presence or absence of honeycomb lung, or pulmonary function tests.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram predicting the outcome of salvage radiation therapy for prostate-specific antigen failure following radical prostatectomy: an exploratory analysis of a randomized, multicenter, open-label, phase 3 trial (JCOG0401).","authors":"Yoichiro Tohi, Akira Yokomizo, Takahiro Kimura, Masashi Wakabayashi, Masaki Shiota, Keiichiro Mori, Takuma Kato, Toyonori Tsuzuki, Masashi Kato, Keita Sasaki, Takashi Kawahara, Masatoshi Eto, Hiroyuki Nishiyama, Hiroshi Kitamura, Mikio Sugimoto","doi":"10.1007/s10147-025-02714-4","DOIUrl":"10.1007/s10147-025-02714-4","url":null,"abstract":"<p><strong>Background: </strong>We have demonstrated that patients with prostate-specific antigen failure following radical prostatectomy benefit from salvage radiation therapy prior to salvage hormone therapy in a multicenter, randomized, open-label, phase 3 trial (JCOG0401). This study aimed to develop a nomogram to predict the efficacy of salvage radiation therapy in patients with prostate-specific antigen failure following radical prostatectomy.</p><p><strong>Methods: </strong>This exploratory study focused on the salvage radiation therapy arm of the JCOG0401 trial and explored clinical factors that were significantly associated with the time to treatment failure of salvage radiation therapy using univariable and multivariable analyses. Based on these factors, we developed a nomogram to predict 3- and 5-year time to treatment failure. Discrimination and calibration of the nomogram were performed using concordance statistics and calibration plots.</p><p><strong>Results: </strong>Ninety-six patients were included in the analysis, with a median time to treatment failure of 4.7 years. Multivariable Cox regression analysis identified pathological T stage ≥ 3, lack of lymph node dissection, lack of nerve-sparing, and prostate-specific antigen-doubling time < 6 months as significant factors associated with time to treatment failure (P < 0.05 for each). The nomogram including these factors achieved a concordance statistics of 0.6996. The hazard ratio for time to treatment failure was 2.946 (95% confidence interval 1.624-5.347), when the cut-off value of the nomogram was determined as the median nomogram score.</p><p><strong>Conclusions: </strong>The developed nomogram enables moderate prediction of the efficacy of salvage radiation therapy in patients with prostate-specific antigen recurrence following radical prostatectomy.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Questionnaire-based survey on the extent of lymph node dissection during interval debulking surgery after neoadjuvant chemotherapy for patients with advanced ovarian cancer in the Gynecologic Cancer Study Group of JCOG.","authors":"Yuki Iida, Mayumi Kobayashi-Kato, Hiroaki Komatsu, Mitsuya Ishikawa, Toyomi Satoh","doi":"10.1007/s10147-025-02734-0","DOIUrl":"https://doi.org/10.1007/s10147-025-02734-0","url":null,"abstract":"<p><strong>Background: </strong>The significance of lymph node dissection (LND) in primary debulking surgery (PDS) for advanced ovarian cancer was demonstrated in the LION trial. However, the role and the current practices of LND during interval debulking surgery (IDS) remains unclear. We aimed to conduct a survey of the current LND practices.</p><p><strong>Methods: </strong>A questionnaire-based survey regarding the criteria and extent of LND for advanced ovarian cancer was conducted by the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group (JCOG). We defined enlarged lymph nodes as 10 mm or more in the short axis on imaging.</p><p><strong>Results: </strong>This study included data from 51 institutions. Factors contributing to the decision regarding the extent of LND included performance status, completeness of cytoreductive surgery excluding the lymph nodes, and age. Regarding PDS cases with enlarged lymph nodes, 90% of all institutions opted for systematic LND (SyLND) or removal of only the enlarged lymph nodes (SeLND). In IDS cases with enlarged lymph nodes after neoadjuvant chemotherapy (NACT), 15 (29%) and 35 (69%) institutions opted for SyLND and SeLND, respectively. In contrast, in IDS cases in which enlarged lymph nodes were reduced after NACT, approximately half the institutions opted for no LND.</p><p><strong>Conclusion: </strong>This study found no established standard treatment for LND during IDS in patients with enlarged lymph nodes among the JCOG institutions. Thus, further prospective studies comparing the prognostic outcomes with or without LND are warranted.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic trachelectomy with sentinel lymph node biopsy for cervical cancer: a prospective study investigating minimally invasive radicality.","authors":"Hiroaki Kobayashi, Shintaro Yanazume, Masaki Kamio, Shinichi Togami, Takashi Ushiwaka","doi":"10.1007/s10147-025-02718-0","DOIUrl":"https://doi.org/10.1007/s10147-025-02718-0","url":null,"abstract":"<p><strong>Objective: </strong>The importance of minimally invasive fertility-sparing surgery for cervical cancer is gaining increasing interest, both to achieve a cure and for future fertility. Procedures for robotic radical trachelectomy involving uterine reconstruction are not fully established.</p><p><strong>Methods: </strong>This study prospectively verified the feasibility and safety of robotic radical trachelectomy between February 2018 and May 2022. The criteria were almost identical to those for our standard abdominal radical trachelectomy. Larger tumors (> 2 cm in diameter) were acceptable for surgery, provided a secure ≥ 1 cm cancer-free space was identified between the tumor and internal os.</p><p><strong>Results: </strong>Eight patients (median age, 32 y) were registered; the median body mass index was 21.8, and the median tumor size was 11.5 mm (range 0-30 mm). Robotic radical trachelectomy could be achieved in all patients with hybrid sentinel lymph node navigation surgery, confirming the precise cervical amputation line with a newer small knob ultrasonography probe, adequate cervical cerclage with non-absorbable monofilament stitches, and avoiding looseness between vaginal-uterine anastomosis with uninterrupted barbed U-shaped sutures. None of the cases were converted to laparotomy or radical hysterectomy, and there were no major complications. The median follow-up period was 49.5 mo (range 21-58 mo) and no patient had disease recurrence.</p><p><strong>Conclusion: </strong>Robotic radical trachelectomy is safe and feasible using newer technologies without reducing radicality; it is also less invasive. Procedures are consistently reproducible and have the potential to be generalized to minimally invasive approaches.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma.","authors":"Azusa Sakurai, Ken Yamaguchi, Kentaro Ishida, Naoki Horikawa, Eri Kawai, Yasushi Kotani, Takaaki Yoshida, Naoya Kishimoto, Keiji Tatsumi, Minami Okudate, Yoko Iemura, Yukiko Taga, Megumi Aki, Yukiko Ando, Akihiro Yanai, Koji Yamanoi, Mana Taki, Ryusuke Murakami, Junzo Hamanishi, Masaki Mandai","doi":"10.1007/s10147-024-02687-w","DOIUrl":"10.1007/s10147-024-02687-w","url":null,"abstract":"<p><strong>Introduction: </strong>Uterine carcinosarcoma (UCS) and uterine sarcomas (US) are rare but aggressive cancer with poor prognoses. The prognostic value of systemic inflammatory response (SIR) indicators, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), in predicting outcomes of UCS and US remains unclear. This study investigated the prognostic significance of SIR indicators for UCS and US.</p><p><strong>Materials and methods: </strong>Clinicopathological data from 237 patients diagnosed with UCS or US across 14 hospitals from January 2008 to December 2017 were retrospectively analyzed. NLR, PLR, and MLR values were calculated from preoperative blood counts. Prognostic impact was evaluated using Kaplan-Meier survival analysis, Cox regression models, and receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>Elevated NLR, PLR, and MLR were associated with poorer progression-free survival (PFS) in UCS. Additionally, a high NLR also indicated worse overall survival (OS) in UCS. In patients with US, only PLR was significantly associated with poorer PFS. Combining SIR indicators provided a stronger prognostic prediction for UCS compared to individual indicators. Multivariate analysis revealed that high levels of SIR indicators were an independent poor prognostic factor for both PFS and OS in UCS.</p><p><strong>Conclusion: </strong>SIR indicators, particularly when combined, are valuable prognostic markers in UCS, reflecting the inflammatory status and aiding in stratifying patients for tailored therapeutic strategies. These findings support the incorporation of SIR indicators into clinical practice for better management of patients with UCS.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"570-583"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma.","authors":"Ryunosuke Nakagawa, Kouji Izumi, Ren Toriumi, Shuhei Aoyama, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroaki Iwamoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Atsushi Mizokami","doi":"10.1007/s10147-024-02678-x","DOIUrl":"10.1007/s10147-024-02678-x","url":null,"abstract":"<p><strong>Background: </strong>Enfortumab vedotin (EV) is a novel treatment for metastatic urothelial carcinoma (mUC) that progresses after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This study aimed to compare the efficacy of EV with that of paclitaxel plus carboplatin therapy (TC), which was commonly used as late-line therapy.</p><p><strong>Methods: </strong>This retrospective study included patients with mUC who progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. Patients were classified into two groups: those who were initiated on EV (EV group) and those who received TC as the next-line treatment (TC group). Therapeutic efficacy and adverse events (AEs) were investigated.</p><p><strong>Results: </strong>A total of 55 patients were included in this study (20 in the TC group and 35 in the EV group). The EV group had significantly better progression-free survival (PFS) (p = 0.0013) and overall survival (OS) (p = 0.0279) than the TC group. The most frequent AEs were neutropenia (70.0%), febrile neutropenia (20.0%), and peripheral neuropathy (20.0%) in the TC group and pruritus (45.7%) and maculopapular rash (37.1%) in the EV group. Patients who progressed after EV administration were classified into two groups: those who received TC (the TC group) and those who were shifted to best supportive care (the BSC group). The TC group had significantly better OS (p = 0.0084).</p><p><strong>Conclusions: </strong>EV was associated with significantly better PFS and OS than TC in patients with mUC who progressed after platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. TC is beneficial for certain patients, even in cases of progression after EV administration.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"524-531"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients.","authors":"Rikako Ito, Masahiro Kagabu, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Tadahiro Shoji, Takashi Hirayama, Yasuhisa Terao, Tsukasa Baba","doi":"10.1007/s10147-024-02682-1","DOIUrl":"10.1007/s10147-024-02682-1","url":null,"abstract":"<p><strong>Background: </strong>The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail. Thus, we comprehensively analyzed cytokines in ascites fluid (AF) and serum before and after CART to determine the influence of cytokines on the safety and efficacy of CART.</p><p><strong>Methods: </strong>Thirteen ovarian cancer patients with refractory malignant ascites who underwent CART were enrolled. We comprehensively analyzed 27 cytokines in AF and serum before and after CART. Simultaneously, vital measurements, blood tests, adverse event recordings, and QOL assessments were performed to examine the relationships between the cytokines in AF and serum.</p><p><strong>Results: </strong>Interleukin (IL)-5, IL-6, IL-10, and monocyte chemoattractant protein-1 levels were increased in the concentrated AF and in the serum immediately after reinfusion, but they decreased after 24 h. Body temperature also increased immediately after reinfusion, and decreased after 24 h. The CRP level at 24 h after reinfusion was increased, and was positively correlated with the IL-6 level. A QOL assessment using the Cancer Fatigue Scale revealed significantly lower scores after CART.</p><p><strong>Conclusions: </strong>The results indicate that the cytokine-induced fever and increased inflammatory response after CART were temporary, and that CART is safe. Additionally, QOL improved after CART. Thus, CART appears safe and effective for treating patients with refractory cancerous ascites.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"559-569"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis.","authors":"Hirotaka Shinomiya, Kazuto Matsuura, Rikiya Onimaru, Akira Ohkoshi, Yuki Saito, Hiroyuki Tachibana, Kiyoto Shiga, Tsutomu Ueda, Yukinori Asada, Hirokazu Uemura, Takeshi Beppu, Akira Seto, Ryuji Yasumatsu, Mitsuhiko Nakahira, Go Omura, Takahiro Asakage, Shujiro Minami, Takashi Fujii, Yuji Hirayama, Daisuke Yoshida, Kenichi Nakamura, Keita Sasaki, Junki Mizusawa, Haruhiko Fukuda, Akihiro Homma","doi":"10.1007/s10147-025-02702-8","DOIUrl":"10.1007/s10147-025-02702-8","url":null,"abstract":"<p><strong>Background: </strong>JCOG1212 is a dose-finding and efficacy confirmatory study of concurrent superselective intra-arterial infusion of cisplatin and radiotherapy (RADPLAT) for locally advanced primary squamous cell carcinoma of the maxillary sinus (cT4a,bN0M0). In this study, we report the results of the final analysis of the efficacy confirmation phase for the T4a cohort with 5-year follow-up data to evaluate the late adverse events and long-term efficacy.</p><p><strong>Methods: </strong>Based on the results of the dose-finding phase, the efficacy confirmation phase consisted of seven weekly intra-arterial infusions of cisplatin 100 mg/m² combined with radiotherapy (70 Gy). The 5-year prognosis and late adverse events were evaluated.</p><p><strong>Results: </strong>Between April 2014 and August 2018, 64 patients were included in the analysis (one ineligible patient was excluded); 31 patients were treated with three-dimensional conformal radiation therapy (3D-CRT) and 33 with intensity modulated radiation therapy (IMRT). The 5-year overall survival, event-free survival, and local event-free survival was 71.9, 54.7, and 57.5%, respectively. In terms of late adverse events, grade 3 or higher non-hematologic toxicity was observed in 42.9% of 63 patients (retinopathy: 12, cataract: 10, osteonecrosis of mandible: 4, etc.). Grade 3 and 4 cataracts of affected side appeared in 22.6% (7/31) of the 3D-CRT group compared to 3.1% (1/32) in the IMRT group. Twenty-one patients had died, with 15 from the primary disease, 5 from other causes, and 1 from treatment-related cause.</p><p><strong>Conclusion: </strong>The prognosis of RADPLAT was favorable after 5-year follow-up with acceptable late adverse events and low proportion of treatment related death.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"489-496"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.","authors":"Hiroaki Nagata, Taku Tsukamoto, Tsutomu Kobayashi, Ryoichi Takahashi, Akira Okano, Hitoji Uchiyama, Eri Kawata, Nobuhiko Uoshima, Hiroto Kaneko, Shin-Ichi Fuchida, Daichi Nishiyama, Mitsushige Nakao, Takahiro Fujino, Shinsuke Mizutani, Yuji Shimura, Junya Kuroda","doi":"10.1007/s10147-025-02691-8","DOIUrl":"10.1007/s10147-025-02691-8","url":null,"abstract":"<p><strong>Background: </strong>While R-CHOP has been one of the standard therapies for untreated high-tumor-burden (HTB) follicular lymphoma (FL) for over 2 decades, obinutuzumab plus bendamustine (OB) is also currently regarded as the standard of care since its approval in 2018 in Japan; however, the long-term efficacy and safety of OB in the daily clinical practice has not been thoroughly evaluated.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study for the clinical outcome of 53 patients with HTB FL treated by OB as the frontline therapy between 2018 and 2021 in the Kyoto Hematology Clinical Study Group (KOTOSG). All patients had at least 2-year follow-up period.</p><p><strong>Results: </strong>The median age was 67, and 60.4% were classified as high risk according to the Follicular Lymphoma International Prognostic Index. The overall and complete response rates after induction therapy with OB were 98% and 83%, respectively. With a median follow-up of 38.5 months, the 3-year progression-free survival (PFS) and overall survival (OS) were 77.3% and 91.2%, respectively. Grade 3-4 hematological adverse events (AEs) were common, including neutropenia (58.5%) and lymphopenia (98.1%). Non-hematological AEs included infections, such as lung infections, coronavirus disease 2019, and sepsis, with two cases (3.8%) being fatal. Finally, propensity score-matched analysis showed no significant difference in PFS between 46 FL patients treated by the frontline OB and 46 FL patients treated by R-CHOP between 2001 and 2019 in KOTOSG.</p><p><strong>Conclusion: </strong>This study highlighted the need for careful treatment selection based on patient background and disease condition in real-world practice with more elderly patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"593-603"},"PeriodicalIF":2.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}